Home Cart Sign in  
Chemical Structure| 865305-30-2 Chemical Structure| 865305-30-2

Structure of AF-353
CAS No.: 865305-30-2

Chemical Structure| 865305-30-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AF-353 is a potent and orally bioavailable P2X3/P2X2/3 receptor antagonist, inhibits human and rat P2X3 (pIC50= 8.0).

Synonyms: Ro-4

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AF-353

CAS No. :865305-30-2
Formula : C14H17IN4O2
M.W : 400.21
SMILES Code : NC1=NC=C(OC2=CC(I)=C(OC)C=C2C(C)C)C(N)=N1
Synonyms :
Ro-4
MDL No. :MFCD18782750
InChI Key :AATPYXMXFBBKFO-UHFFFAOYSA-N
Pubchem ID :15953802

Safety of AF-353

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
AF-353 (Ro-4) is a potent, selective, and orally bioavailable antagonist of P2X3 and P2X2/3 receptors, with a pIC50 of 8.0 for both human and rat P2X3, and a pIC50 of 7.3 for human P2X2/3[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK-293 cells 12.9±0.5 nM Inhibition of hP2X3 by AF-353 Proc Natl Acad Sci U S A. 2018 May 8;115(19):4939-4944
5-HT3A-GFP expressing neurons 100 µM To test the effect of AF-353 on 5-HT3 receptors, results showed that AF-353 had no effect on 5-HT-induced Ca2+ responses. J Physiol. 2015 Mar 1;593(5):1113-25
geniculate ganglion neurons from P2X3 single knockout mice 10 µM or 100 µM To test the specificity of AF-353 for P2X3-containing receptors, results showed that AF-353 had no inhibitory effect on geniculate ganglion neurons from P2X3 single knockout mice. J Physiol. 2015 Mar 1;593(5):1113-25
guinea pig vagal nodose C-fibers 100 μM 20 min AF-353 significantly inhibited histamine-induced action potential discharge in nodose C-fibers, reducing the total number of action potentials from 123±32 to 21±5 and peak frequency from 8±1 Hz to 3±1 Hz. J Physiol. 2012 Aug 15;590(16):4109-20

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Female Sprague-Dawley rats Spinal cord-injured (SCI) rat model Intravenous injection 10 mg/kg and 20 mg/kg Two injections, 90 minutes apart To evaluate the effect of AF-353 on bladder sensory pathways in normal and SCI rats. Results showed that AF-353 significantly reduced the frequency of spinal neural activity and non-voiding contractions (NVCs) in both normal and SCI rats. BJU Int. 2012 Oct;110(8 Pt B):E409-14
Female Sprague-Dawley rats Spinal cord injury model (moderate or severe) Intravesical administration 10 μM 20 – 40 minutes To evaluate the role of P2X2/3R in early and advanced neurogenic lower urinary tract dysfunction following spinal cord injury. Results showed that intravesical P2X2/3R inhibition could attenuate electrical activity in the neurogenic LUT at early stages but not at semi-chronic SCI. BJU Int. 2019 Mar;123(3):538-547

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.50mL

0.50mL

0.25mL

12.49mL

2.50mL

1.25mL

24.99mL

5.00mL

2.50mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories